Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate

Featured News
Lassa Virus under a microscope

The GW VRU was a site for the phase 1, double-blind clinical trial to examine the safety and immunogenicity of a replication-competent recombinant vesicular stomatitis virus-vectored vaccine to reduce the risk of infection and severe illness from Lassa Fever. A total of 114 adults were enrolled, and no serious vaccine-related adverse events were reported. The vaccine had immunogenicity across the study population in the United States and Liberia.

 

 

Photo Credit: AMI IMAGES / SCIENCE PHOTO LIBRARY

Click here to read more!
vaccine

Latest News

An omicron COVID virus. A gray virus with red and orange projections.
The effect of Omicron BA.1-based booster mRNA vaccination on the incidence of COVID-19
The GW VRU is pleased to share the findings from a Phase 2 clinical trial that evaluated the effects of omicron-based COVID-19 vaccines in providing an increased level of protection against COVID-19 infection. This study adds to the evidence that matching COVID-19 vaccines to the circulating…
This is an HIV antibody with a yellow core and pink outer shell.
Targeting HIV broadly neutralizing antibody precursors with precision in humans.
A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. This study provides proof-of-concept for Env trimer-based GT approaches to activate bnAb precursors and induce affinity maturation on the…
Picture of antibodies.
HIV vaccine using mRNA-encoded nanoparticles showed to be safe and well-tolerated
The GW VRU participated in IAVI-G002 as a clinical site for a phase 1 human clinical trial. This study evaluated the safety and immunogenicity of mRNA-encoded nanoparticles as priming immunogens and first-boosting immunogens (IAVI-G002).